The need for new medicines never stops, and Orion has continued its research operations to the best of its ability even during the coronavirus pandemic. Patient safety and the integrity of research is never compromised.
There is good availability of the medicines needed by Finns. Orion has increased production of several products during the spring.
For years, the pharmaceutical industry has carried out proactive risk assessment and management on their global supply chains to ensure that medicines remain available at competitive prices.
We answer the most common questions related to the availability of Orion’s pharmaceutical products.
The coronavirus pandemic has not compromised the supply of medicines in Finland or the rest of the EU. However, should the pandemic continue for a prolonged period, the availability of medicines may be affected.
Drug development from molecular level innovation to marketable product is rarely possible without collaboration and partnerships. Contract manufacturing allows pharmaceutical companies to outsource specific stages of development work to providers with the best available niche expertise.
New digital tools benefit both patients and health care professionals, helping improve the treatment of Parkinson's disease, for example. They may also help ease the challenges of rising health care costs for public spending.
This is Orion’s third year as a main sponsor of the John Nurminen Foundation. The Foundation’s new Baltic Sea campaigns will help minimise fertiliser emissions at ports and collect our fondest memories of the Baltic Sea.
A new research ecosystem has been set up in Finland in which the country’s leading research organisations, together with the Finnish Red Cross Blood Service, Orion Pharma and nanotechnology SMEs, are joining forces to develop new types of nanobiotechnological solutions for the treatment and early diagnostics of severe progressive diseases.
Orion implements responsible medication and states in its value proposition that it wants to be a medicine cabinet for Finns. Based on this, Orion is the sole manufacturer or distributor of many pharmaceuticals in Finland.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
Going abroad was an important career move for Sara Sammallahti. A grant of EUR 50,000 from the Orion Research Foundation made it possible for her to join a group of Dutch and American researchers. Sammallahti is studying the effects of the mother’s well-being during pregnancy on the brain of the foetus.
A novel screening method enables faster and more accurate measurement.
The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.
Thanks to biosimilars, an increasing number of patients can receive effective care at a lower pharmaceutical cost.
In Universum’s student survey on ideal workplaces Orion was ranked fourth by natural science students.